Goldman Sachs
DXCM icon

Goldman Sachs’s DexCom DXCM Stock Holding History

Goldman Sachs’s Portfolio DXCM Stock Details DXCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$29.9M Sell
475,400
-59,200
-11% -$4.12M ﹤0.01% 2069
2025
Q4 		$35.5M Buy
534,600
+152,600
+40% +$9.87M ﹤0.01% 1797
2025
Q3 		$25.7M Buy
382,000
+53,700
+16% +$4.25M ﹤0.01% 2007
2025
Q2 		$28.7M Buy
328,300
+153,700
+88% +$12M ﹤0.01% 1801
2025
Q1 		$11.9M Buy
+174,600
New +$14.2M ﹤0.01% 2528
2024
Q4 		– Sell
-15,000
Closed -$1.01M – 6084
2024
Q3 		$1.01M Sell
15,000
-3,000
-17% -$246K ﹤0.01% 4629
2024
Q2 		$2.04M Buy
18,000
+15,000
+500% +$1.9M ﹤0.01% 3897
2024
Q1 		$416K Sell
3,000
-3,600
-55% -$453K ﹤0.01% 4832
2023
Q4 		$819K Buy
+6,600
New +$674K ﹤0.01% 4494
2023
Q3 		– Sell
-40,000
Closed -$5.14M – 5623
2023
Q2 		$5.14M Buy
+40,000
New +$4.84M ﹤0.01% 3089
2022
Q3 		– Sell
-50,000
Closed -$3.73M – 6325
2022
Q2 		$3.73M Buy
+50,000
New +$4.56M ﹤0.01% 3456
2022
Q1 		– Sell
-237,600
Closed -$31.9M – 6632
2021
Q4 		$31.9M Buy
237,600
+186,400
+364% +$26.8M 0.01% 1711
2021
Q3 		$7M Hold
51,200
– – ﹤0.01% 3060
2021
Q2 		$5.47M Hold
51,200
– – ﹤0.01% 3263
2021
Q1 		$4.6M Sell
51,200
-54,000
-51% -$5.07M ﹤0.01% 3210
2020
Q4 		$9.72M Buy
105,200
+33,600
+47% +$3M ﹤0.01% 2489
2020
Q3 		$7.38M Buy
71,600
+58,000
+426% +$6.06M ﹤0.01% 2583
2020
Q2 		$1.38M Buy
13,600
+3,600
+36% +$322K ﹤0.01% 3736
2020
Q1 		$673K Buy
+10,000
New +$622K ﹤0.01% 4027
2014
Q2 		– Sell
-200,000
Closed -$2.07M – 7011
2014
Q1 		$2.07M Sell
200,000
-5,200
-3% -$53.7K ﹤0.01% 3938
2013
Q4 		$1.82M Sell
205,200
-1,683,600
-89% -$13.3M ﹤0.01% 4174
2013
Q3 		$13.3M Buy
1,888,800
+1,688,800
+844% +$10.7M ﹤0.01% 1959
2013
Q2 		$1.12M Buy
+200,000
New +$958K ﹤0.01% 4287

Other funds holding DXCM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Goldman Sachs's DXCM Position: Q1 2026 in Review

Goldman Sachs increased its DexCom (DXCM) stake by 25% in Q1 2026, buying an estimated $42.2M and bringing the position to 3,043,635 shares worth $191M. The position accounts for 0.02% of the portfolio, ranked #695.

Goldman Sachs first reported a position in DXCM in Q2 2013 and has held it in 52 quarters since. The position peaked at $495M in Q2 2020. 956 funds tracked by Wall St. Rank hold DXCM as of Q1 2026.

  • Goldman Sachs held 3,043,635 shares of DexCom worth $191M as of Q1 2026.
  • Goldman Sachs bought 605,788 DexCom shares in Q1 2026, an estimated $42.2M.
  • DexCom made up 0.02% of Goldman Sachs's portfolio in Q1 2026, its #695 holding.
  • Goldman Sachs first reported a position in DexCom in Q2 2013 and has held it in 52 quarters since.
  • Goldman Sachs's DexCom position peaked at $495M in Q2 2020.
  • 956 funds tracked by Wall St. Rank held DexCom as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.